URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Philip Fay

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentBiochemistry and Biophysics
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 712
Rochester NY 14642
 
 Overview
Factor VIII serves as a protein cofactor for the serine protease, factor IXa in the surface-dependent conversion of factor X to factor Xa during the blood coagulation cascade reactions. Deficiency or defects in factor VIII result in hemophilia A, the most common of the severe, inherited bleeding disorders. Ongoing studies in our laboratory include physical and biochemical analyses of factor VIII structure and inter-subunit interactions. We are particularly interested in study of the activated form of the cofactor, factor VIIIa, which consists of a labile heterotrimeric structure. Additional studies assess functional changes reflecting altered structure following interaction of factor VIII/factor VIIIa with effector molecules (serine proteases) such as thrombin and activated protein C.

The role of factor VIIIa is to increase the kcat of factor IXa by several orders of magnitude. Little is known about the mechanism by which this is achieved. A second major focus of our lab is to elucidate the molecular basis for the cofactor effect following reconstitution of the intrinsic factor Xase complex (factor IXa, factor VIIIa (or isolated subunits) plus phospholipid vesicles) using purified components.

These projects are complemented by the generation and analysis of recombinant proteins possessing point mutations at sites proposed to contribute to intra- and inter-protein interactions. Overall, our research program is aimed at gaining fundamental insights into the structure, activity and regulation of a protein central to hemostasis.

 
 Selected Publications
List All   |   Timeline
  1. Griffiths AE, Wintermute J, Newell-Caito JL, Fay PJ. Residues Flanking Scissile Bonds in Factor VIII Modulate Rates of Cleavage and Proteolytic Activation Catalyzed by Factor Xa. Biochemistry. 2013 Nov 12; 52(45):8060-8.
    View in: PubMed
  2. Wakabayashi H, Fay PJ. Replacing the Factor VIII C1 Domain with a Second C2 Domain Reduces Factor VIII Stability and Affinity for Factor IXa. J Biol Chem. 2013 Oct 25; 288(43):31289-97.
    View in: PubMed
  3. Wakabayashi H, Fay PJ. Molecular orientation of Factor VIIIa on the phospholipid membrane surface determined by fluorescence resonance energy transfer. Biochem J. 2013 Jun 1; 452(2):293-301.
    View in: PubMed
  4. Wakabayashi H, Fay PJ. Modification of Interdomain Interfaces within the A3C1C2 Subunit of Factor VIII Affects Its Stability and Activity. Biochemistry. 2013 Jun 4; 52(22):3921-9.
    View in: PubMed
  5. Griffiths AE, Rydkin I, Fay PJ. Factor VIIIa A2 Subunit Shows a High Affinity Interaction with Factor IXa: CONTRIBUTION OF A2 SUBUNIT RESIDUES 707-714 TO THE INTERACTION WITH FACTOR IXa. J Biol Chem. 2013 May 24; 288(21):15057-64.
    View in: PubMed
  6. Takeyama M, Wintermute JM, Manithody C, Rezaie AR, Fay PJ. Variable Contributions of Basic Residues Forming an APC Exosite in the Binding and Inactivation of Factor VIIIa. Biochemistry. 2013 Apr 2; 52(13):2228-35.
    View in: PubMed
  7. Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima M. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost. 2013 Jun 4; 109(6):1007-15.
    View in: PubMed
  8. Takeyama M, Wakabayashi H, Fay PJ. Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site. Thromb Haemost. 2013 Jan 31; 109(2):187-98.
    View in: PubMed
  9. Newell-Caito JL, Griffiths AE, Fay PJ. P3-P3' Residues Flanking Scissile Bonds in Factor VIII Modulate Rates of Substrate Cleavage and Procofactor Activation by Thrombin. Biochemistry. 2012 Apr 24; 51(16):3451-9.
    View in: PubMed
  10. DeAngelis JP, Wakabayashi H, Fay PJ. Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalyzed cleavage rates at this site and cofactor function. J Biol Chem. 2012 May 4; 287(19):15409-17.
    View in: PubMed
  11. Wakabayashi H, Griffiths AE, Fay PJ. Enhancing factor VIII and VIIIa stability by combining mutations at the A2 domain interface and A1-C2 domain interface. J Thromb Haemost. 2012 Mar; 10(3):492-5.
    View in: PubMed
  12. Takeyama M, Wakabayashi H, Fay PJ. Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry. 2012 Jan 24; 51(3):820-8.
    View in: PubMed
  13. Griffiths AE, Wang W, Hagen FK, Fay PJ. Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction. J Thromb Haemost. 2011 Aug; 9(8):1534-40.
    View in: PubMed
  14. Wakabayashi H, Griffiths AE, Fay PJ. Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability. J Biol Chem. 2011 Jul 22; 286(29):25748-55.
    View in: PubMed
  15. DeAngelis JP, Varfaj F, Wakabayashi H, Fay PJ. The role of P4-P3' residues flanking Arg336 in facilitating activated protein C-catalyzed cleavage and inactivation of factor VIIIa. Thromb Res. 2011 Nov; 128(5):470-6.
    View in: PubMed
  16. Novakovic VA, Cullinan DB, Wakabayashi H, Fay PJ, Baleja JD, Gilbert GE. Membrane-binding properties of the Factor VIII C2 domain. Biochem J. 2011 Apr 1; 435(1):187-96.
    View in: PubMed
  17. Wakabayashi H, Griffiths AE, Fay PJ. Factor VIII lacking the C2 domain retains cofactor activity in vitro. J Biol Chem. 2010 Aug 13; 285(33):25176-84.
    View in: PubMed
  18. Jagannathan I, Ichikawa HT, Kruger T, Fay PJ. Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXa. J Biol Chem. 2009 Nov 20; 284(47):32248-55.
    View in: PubMed
  19. Newell JL, Fay PJ. Cleavage at Arg-1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII. J Biol Chem. 2009 Apr 24; 284(17):11080-9.
    View in: PubMed
  20. Wakabayashi H, Griffiths AE, Fay PJ. Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations. J Thromb Haemost. 2009 Mar; 7(3):438-44.
    View in: PubMed
  21. Wakabayashi H, Varfaj F, Deangelis J, Fay PJ. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood. 2008 Oct 1; 112(7):2761-9.
    View in: PubMed
  22. Newell JL, Fay PJ. Acidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII. Biochemistry. 2008 Aug 19; 47(33):8786-95.
    View in: PubMed
  23. Wakabayashi H, Fay PJ. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa. J Biol Chem. 2008 Apr 25; 283(17):11645-51.
    View in: PubMed
  24. Newell JL, Fay PJ. Proteolysis at Arg740 facilitates subsequent bond cleavages during thrombin-catalyzed activation of factor VIII. J Biol Chem. 2007 Aug 31; 282(35):25367-75.
    View in: PubMed
  25. Varfaj F, Wakabayashi H, Fay PJ. Residues surrounding Arg336 and Arg562 contribute to the disparate rates of proteolysis of factor VIIIa catalyzed by activated protein C. J Biol Chem. 2007 Jul 13; 282(28):20264-72.
    View in: PubMed
  26. Wakabayashi H, Zhou Q, Varfaj F, Fay PJ. A3 domain residue Glu1829 contributes to A2 subunit retention in factor VIIIa. J Thromb Haemost. 2007 May; 5(5):996-1001.
    View in: PubMed
  27. Ansong C, Miles SM, Fay PJ. Factor VIII A1 domain residues 97-105 represent a light chain-interactive site. Biochemistry. 2006 Nov 7; 45(44):13140-9.
    View in: PubMed
  28. Varfaj F, Neuberg J, Jenkins PV, Wakabayashi H, Fay PJ. Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa. Biochem J. 2006 Jun 1; 396(2):355-62.
    View in: PubMed
  29. Wakabayashi H, Zhou Q, Nogami K, Ansong C, Varfaj F, Miles S, Fay PJ. pH-dependent association of factor VIII chains: enhancement of affinity at physiological pH by Cu2+. Biochim Biophys Acta. 2006 Jun; 1764(6):1094-101.
    View in: PubMed
  30. Ansong C, Miles SM, Fay PJ. Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12. J Thromb Haemost. 2006 Apr; 4(4):842-7.
    View in: PubMed
  31. Fay PJ. Factor VIII structure and function. Int J Hematol. 2006 Feb; 83(2):103-8.
    View in: PubMed
  32. Wakabayashi H, Su YC, Ahmad SS, Walsh PN, Fay PJ. A Glu113Ala mutation within a factor VIII Ca2+-binding site enhances cofactor interactions in factor Xase. Biochemistry. 2005 Aug 2; 44(30):10298-304.
    View in: PubMed
  33. Ansong C, Fay PJ. Factor VIII A3 domain residues 1954-1961 represent an A1 domain-interactive site. Biochemistry. 2005 Jun 21; 44(24):8850-7.
    View in: PubMed
  34. Nogami K, Zhou Q, Myles T, Leung LL, Wakabayashi H, Fay PJ. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J Biol Chem. 2005 May 6; 280(18):18476-87.
    View in: PubMed
  35. Nogami K, Zhou Q, Wakabayashi H, Fay PJ. Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site. Blood. 2005 Jun 1; 105(11):4362-8.
    View in: PubMed
  36. Fay PJ, Jenkins PV. Mutating factor VIII: lessons from structure to function. Blood Rev. 2005 Jan; 19(1):15-27.
    View in: PubMed
  37. Nogami K, Wakabayashi H, Ansong C, Fay PJ. Localization of a pH-dependent, A2 subunit-interactive surface within the factor VIIIa A1 subunit. Biochim Biophys Acta. 2004 Sep 1; 1701(1-2):25-35.
    View in: PubMed
  38. Nogami K, Freas J, Manithody C, Wakabayashi H, Rezaie AR, Fay PJ. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem. 2004 Aug 6; 279(32):33104-13.
    View in: PubMed
  39. Jenkins PV, Dill JL, Zhou Q, Fay PJ. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry. 2004 May 4; 43(17):5094-101.
    View in: PubMed
  40. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 2004 Mar; 18(1):1-15.
    View in: PubMed
  41. Jenkins PV, Dill JL, Zhou Q, Fay PJ. Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. J Thromb Haemost. 2004 Mar; 2(3):452-8.
    View in: PubMed
  42. Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem. 2004 Apr 16; 279(16):15763-71.
    View in: PubMed
  43. Wakabayashi H, Freas J, Zhou Q, Fay PJ. Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity. J Biol Chem. 2004 Mar 26; 279(13):12677-84.
    View in: PubMed
  44. Peng H, Sahni A, Fay P, Bellum S, Prudovsky I, Maciag T, Francis CW. Identification of a binding site on human FGF-2 for fibrinogen. Blood. 2004 Mar 15; 103(6):2114-20.
    View in: PubMed
  45. Balakrishnan M, Roques BP, Fay PJ, Bambara RA. Template dimerization promotes an acceptor invasion-induced transfer mechanism during human immunodeficiency virus type 1 minus-strand synthesis. J Virol. 2003 Apr; 77(8):4710-21.
    View in: PubMed
  46. Nogami K, Wakabayashi H, Fay PJ. Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation. J Biol Chem. 2003 May 9; 278(19):16502-9.
    View in: PubMed
  47. Manithody C, Fay PJ, Rezaie AR. Exosite-dependent regulation of factor VIIIa by activated protein C. Blood. 2003 Jun 15; 101(12):4802-7.
    View in: PubMed
  48. Wakabayashi H, Zhen Z, Schmidt KM, Fay PJ. Mn2+ binding to factor VIII subunits and its effect on cofactor activity. Biochemistry. 2003 Jan 14; 42(1):145-53.
    View in: PubMed
  49. Chen Y, Balakrishnan M, Roques BP, Fay PJ, Bambara RA. Mechanism of minus strand strong stop transfer in HIV-1 reverse transcription. J Biol Chem. 2003 Mar 7; 278(10):8006-17.
    View in: PubMed
  50. Nogami K, Wakabayashi H, Schmidt K, Fay PJ. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem. 2003 Jan 17; 278(3):1634-41.
    View in: PubMed
  51. Roda RH, Balakrishnan M, Kim JK, Roques BP, Fay PJ, Bambara RA. Strand transfer occurs in retroviruses by a pause-initiated two-step mechanism. J Biol Chem. 2002 Dec 6; 277(49):46900-11.
    View in: PubMed
  52. Jenkins PV, Freas J, Schmidt KM, Zhou Q, Fay PJ. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood. 2002 Jul 15; 100(2):501-8.
    View in: PubMed
  53. Wakabayashi H, Schmidt KM, Fay PJ. Ca(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity. Biochemistry. 2002 Jul 2; 41(26):8485-92.
    View in: PubMed
  54. Wisniewski M, Chen Y, Balakrishnan M, Palaniappan C, Roques BP, Fay PJ, Bambara RA. Substrate requirements for secondary cleavage by HIV-1 reverse transcriptase RNase H. J Biol Chem. 2002 Aug 9; 277(32):28400-10.
    View in: PubMed
  55. Koszelak Rosenblum ME, Schmidt K, Freas J, Mastri M, Fay PJ. Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg336. J Biol Chem. 2002 Apr 5; 277(14):11664-9.
    View in: PubMed
  56. Wakabayashi H, Koszelak ME, Mastri M, Fay PJ. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry. 2001 Aug 28; 40(34):10293-300.
    View in: PubMed
  57. Fay PJ, Mastri M, Koszelak ME. Factor VIIIa cofactor activity shows enhanced ionic strength sensitivity in the absence of phospholipid. Biochim Biophys Acta. 2001 Jul 9; 1548(1):159-68.
    View in: PubMed
  58. Balakrishnan M, Fay PJ, Bambara RA. The kissing hairpin sequence promotes recombination within the HIV-I 5' leader region. J Biol Chem. 2001 Sep 28; 276(39):36482-92.
    View in: PubMed
  59. Bajaj SP, Schmidt AE, Mathur A, Padmanabhan K, Zhong D, Mastri M, Fay PJ. Factor IXa:factor VIIIa interaction. helix 330-338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa. J Biol Chem. 2001 May 11; 276(19):16302-9.
    View in: PubMed
  60. Fay PJ, Mastri M, Koszelak ME, Wakabayashi H. Cleavage of factor VIII heavy chain is required for the functional interaction of a2 subunit with factor IXA. J Biol Chem. 2001 Apr 13; 276(15):12434-9.
    View in: PubMed
  61. Wisniewski M, Balakrishnan M, Palaniappan C, Fay PJ, Bambara RA. The sequential mechanism of HIV reverse transcriptase RNase H. J Biol Chem. 2000 Dec 1; 275(48):37664-71.
    View in: PubMed
  62. Wisniewski M, Balakrishnan M, Palaniappan C, Fay PJ, Bambara RA. Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):11978-83.
    View in: PubMed
  63. Koszelak ME, Huggins CF, Fay PJ. Sites in the A2 subunit involved in the interfactor VIIIa interaction. J Biol Chem. 2000 Sep 1; 275(35):27137-44.
    View in: PubMed
  64. Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol. 2000 Sep; 74(18):8390-401.
    View in: PubMed
  65. O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood. 2000 Mar 1; 95(5):1714-20.
    View in: PubMed
  66. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem. 1999 Oct 15; 274(42):29826-30.
    View in: PubMed
  67. Wisniewski M, Palaniappan C, Fu Z, Le Grice SF, Fay P, Bambara RA. Mutations in the primer grip region of HIV reverse transcriptase can increase replication fidelity. J Biol Chem. 1999 Oct 1; 274(40):28175-84.
    View in: PubMed
  68. Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost. 1999 Aug; 82(2):193-200.
    View in: PubMed
  69. Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J Virol. 1999 Jul; 73(7):5803-13.
    View in: PubMed
  70. Fay PJ, Koshibu K, Mastri M. The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity. J Biol Chem. 1999 May 28; 274(22):15401-6.
    View in: PubMed
  71. Lapan KA, Fay PJ. Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost. 1998 Sep; 80(3):418-22.
    View in: PubMed
  72. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998 Jul 24; 273(30):19049-54.
    View in: PubMed
  73. Sudhakar K, Fay PJ. Effects of copper on the structure and function of factor VIII subunits: evidence for an auxiliary role for copper ions in cofactor activity. Biochemistry. 1998 May 12; 37(19):6874-82.
    View in: PubMed
  74. Pieneman WC, Fay P, Briët E, Reitsma PH, Bertina RM. Partial reconstitution of factor VIII activity from a mild Crm+ hemophilia A patient by replacement of the defective A2 domain. Thromb Haemost. 1998 May; 79(5):943-8.
    View in: PubMed
  75. Siddiqi F, Odrljin TM, Fay PJ, Cox C, Francis CW. Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. Blood. 1998 Mar 15; 91(6):2019-25.
    View in: PubMed
  76. Palaniappan C, Kim JK, Wisniewski M, Fay PJ, Bambara RA. Control of initiation of viral plus strand DNA synthesis by HIV reverse transcriptase. J Biol Chem. 1998 Feb 13; 273(7):3808-16.
    View in: PubMed
  77. O'Brien LM, Huggins CF, Fay PJ. Interacting regions in the A1 and A2 subunits of factor VIIIa identified by zero-length cross-linking. Blood. 1997 Nov 15; 90(10):3943-50.
    View in: PubMed
  78. Kim JK, Palaniappan C, Wu W, Fay PJ, Bambara RA. Evidence for a unique mechanism of strand transfer from the transactivation response region of HIV-1. J Biol Chem. 1997 Jul 4; 272(27):16769-77.
    View in: PubMed
  79. Lu Y, Planelles V, Li X, Palaniappan C, Day B, Challita-Eid P, Amado R, Stephens D, Kohn DB, Bakker A, Fay P, Bambara RA, Rosenblatt JD. Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem. 1997 Jun 6; 272(23):14523-31.
    View in: PubMed
  80. Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, Bambara RA. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. J Biol Chem. 1997 Apr 25; 272(17):11157-64.
    View in: PubMed
  81. Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem. 1997 Jan 24; 272(4):2082-8.
    View in: PubMed
  82. Fuentes GM, Palaniappan C, Fay PJ, Bambara RA. Strand displacement synthesis in the central polypurine tract region of HIV-1 promotes DNA to DNA strand transfer recombination. J Biol Chem. 1996 Nov 22; 271(47):29605-11.
    View in: PubMed
  83. Sudhakar K, Fay PJ. Exposed hydrophobic sites in factor VIII and isolated subunits. J Biol Chem. 1996 Sep 20; 271(38):23015-21.
    View in: PubMed
  84. Palaniappan C, Wisniewski M, Wu W, Fay PJ, Bambara RA. Misincorporation by HIV-1 reverse transcriptase promotes recombination via strand transfer synthesis. J Biol Chem. 1996 Sep 13; 271(37):22331-8.
    View in: PubMed
  85. Fuentes GM, Fay PJ, Bambara RA. Relationship between plus strand DNA synthesis removal of downstream segments of RNA by human immunodeficiency virus, murine leukemia virus and avian myeloblastoma virus reverse transcriptases. Nucleic Acids Res. 1996 May 1; 24(9):1719-26.
    View in: PubMed
  86. Wu W, Palaniappan C, Bambara RA, Fay PJ. Differences in mutagenesis during minus strand, plus strand and strand transfer (recombination) synthesis of the HIV-1 gene in vitro. Nucleic Acids Res. 1996 May 1; 24(9):1710-8.
    View in: PubMed
  87. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem. 1996 Mar 15; 271(11):6027-32.
    View in: PubMed
  88. Regan LM, O'Brien LM, Beattie TL, Sudhakar K, Walker FJ, Fay PJ. Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase. J Biol Chem. 1996 Feb 23; 271(8):3982-7.
    View in: PubMed
  89. Palaniappan C, Fuentes GM, Rodríguez-Rodríguez L, Fay PJ, Bambara RA. Helix structure and ends of RNA/DNA hybrids direct the cleavage specificity of HIV-1 reverse transcriptase RNase H. J Biol Chem. 1996 Jan 26; 271(4):2063-70.
    View in: PubMed
  90. Fuentes GM, Rodríguez-Rodríguez L, Palaniappan C, Fay PJ, Bambara RA. Strand displacement synthesis of the long terminal repeats by HIV reverse transcriptase. J Biol Chem. 1996 Jan 26; 271(4):1966-71.
    View in: PubMed
  91. Fuentes GM, Rodríguez-Rodríguez L, Fay PJ, Bambara RA. Use of an oligoribonucleotide containing the polypurine tract sequence as a primer by HIV reverse transcriptase. J Biol Chem. 1995 Nov 24; 270(47):28169-76.
    View in: PubMed
  92. O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem. 1995 Nov 10; 270(45):27087-92.
    View in: PubMed
  93. Rodríguez-Rodríguez L, Tsuchihashi Z, Fuentes GM, Bambara RA, Fay PJ. Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by the reverse transcriptase in vitro. J Biol Chem. 1995 Jun 23; 270(25):15005-11.
    View in: PubMed
  94. Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem. 1995 Apr 14; 270(15):8546-52.
    View in: PubMed
  95. Palaniappan C, Fay PJ, Bambara RA. Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chem. 1995 Mar 3; 270(9):4861-9.
    View in: PubMed
  96. Wu W, Blumberg BM, Fay PJ, Bambara RA. Strand transfer mediated by human immunodeficiency virus reverse transcriptase in vitro is promoted by pausing and results in misincorporation. J Biol Chem. 1995 Jan 6; 270(1):325-32.
    View in: PubMed
  97. Bambara RA, Fay PJ, Mallaber LM. Methods of analyzing processivity. Methods Enzymol. 1995; 262:270-80.
    View in: PubMed
  98. DeStefano JJ, Wu W, Seehra J, McCoy J, Laston D, Albone E, Fay PJ, Bambara RA. Characterization of an RNase H deficient mutant of human immunodeficiency virus-1 reverse transcriptase having an aspartate to asparagine change at position 498. Biochim Biophys Acta. 1994 Oct 18; 1219(2):380-8.
    View in: PubMed
  99. DeStefano JJ, Mallaber LM, Fay PJ, Bambara RA. Quantitative analysis of RNA cleavage during RNA-directed DNA synthesis by human immunodeficiency and avian myeloblastosis virus reverse transcriptases. Nucleic Acids Res. 1994 Sep 11; 22(18):3793-800.
    View in: PubMed
  100. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994 Aug 12; 269(32):20522-7.
    View in: PubMed
  101. Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J Biol Chem. 1994 Apr 1; 269(13):9445-52.
    View in: PubMed
  102. DeStefano JJ, Bambara RA, Fay PJ. The mechanism of human immunodeficiency virus reverse transcriptase-catalyzed strand transfer from internal regions of heteropolymeric RNA templates. J Biol Chem. 1994 Jan 7; 269(1):161-8.
    View in: PubMed
  103. Buiser RG, Bambara RA, Fay PJ. Pausing by retroviral DNA polymerases promotes strand transfer from internal regions of RNA donor templates to homopolymeric acceptor templates. Biochim Biophys Acta. 1993 Oct 19; 1216(1):20-30.
    View in: PubMed
  104. Lawrence SO, Wright TW, Francis CW, Fay PJ, Haidaris PJ. Purification and functional characterization of homodimeric gamma B-gamma B fibrinogen from rat plasma. Blood. 1993 Oct 15; 82(8):2406-13.
    View in: PubMed
  105. DeStefano JJ, Mallaber LM, Fay PJ, Bambara RA. Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase. Nucleic Acids Res. 1993 Sep 11; 21(18):4330-8.
    View in: PubMed
  106. Fay PJ, Haidaris PJ, Huggins CF. Role of the COOH-terminal acidic region of A1 subunit in A2 subunit retention in human factor VIIIa. J Biol Chem. 1993 Aug 25; 268(24):17861-6.
    View in: PubMed
  107. DeStefano JJ, Bambara RA, Fay PJ. Parameters that influence the binding of human immunodeficiency virus reverse transcriptase to nucleic acid structures. Biochemistry. 1993 Jul 13; 32(27):6908-15.
    View in: PubMed
  108. Fay PJ. Factor VIII structure and function. Thromb Haemost. 1993 Jul 1; 70(1):63-7.
    View in: PubMed
  109. Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol. 1993; 222:128-43.
    View in: PubMed
  110. Lamphear BJ, Fay PJ. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa. Blood. 1992 Dec 15; 80(12):3120-6.
    View in: PubMed
  111. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem. 1992 Nov 25; 267(33):23652-7.
    View in: PubMed
  112. DeStefano JJ, Mallaber LM, Rodriguez-Rodriguez L, Fay PJ, Bambara RA. Requirements for strand transfer between internal regions of heteropolymer templates by human immunodeficiency virus reverse transcriptase. J Virol. 1992 Nov; 66(11):6370-8.
    View in: PubMed
  113. DeStefano JJ, Buiser RG, Mallaber LM, Fay PJ, Bambara RA. Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates. Biochim Biophys Acta. 1992 Jul 15; 1131(3):270-80.
    View in: PubMed
  114. Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem. 1992 Jul 5; 267(19):13246-50.
    View in: PubMed
  115. Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J. 1992 May; 6(8):2561-7.
    View in: PubMed
  116. Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J Biol Chem. 1992 Feb 25; 267(6):3725-30.
    View in: PubMed
  117. DeStefano JJ, Buiser RG, Mallaber LM, Bambara RA, Fay PJ. Human immunodeficiency virus reverse transcriptase displays a partially processive 3' to 5' endonuclease activity. J Biol Chem. 1991 Dec 25; 266(36):24295-301.
    View in: PubMed
  118. Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991 Oct 25; 266(30):20139-45.
    View in: PubMed
  119. Buiser RG, DeStefano JJ, Mallaber LM, Fay PJ, Bambara RA. Requirements for the catalysis of strand transfer synthesis by retroviral DNA polymerases. J Biol Chem. 1991 Jul 15; 266(20):13103-9.
    View in: PubMed
  120. Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem. 1991 May 15; 266(14):8957-62.
    View in: PubMed
  121. DeStefano JJ, Buiser RG, Mallaber LM, Myers TW, Bambara RA, Fay PJ. Polymerization and RNase H activities of the reverse transcriptases from avian myeloblastosis, human immunodeficiency, and Moloney murine leukemia viruses are functionally uncoupled. J Biol Chem. 1991 Apr 25; 266(12):7423-31.
    View in: PubMed
  122. Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem. 1991 Feb 5; 266(4):2172-7.
    View in: PubMed
  123. Fowler WE, Fay PJ, Arvan DS, Marder VJ. Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. Proc Natl Acad Sci U S A. 1990 Oct; 87(19):7648-52.
    View in: PubMed
  124. Fay PJ, Smudzin TM. Topography of the human factor VIII-von Willebrand factor complex. J Biol Chem. 1990 Apr 15; 265(11):6197-202.
    View in: PubMed
  125. Walker FJ, Fay PJ. Characterization of an interaction between protein C and ceruloplasmin. J Biol Chem. 1990 Feb 5; 265(4):1834-6.
    View in: PubMed
  126. Walker FJ, Scandella D, Fay PJ. Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem. 1990 Jan 25; 265(3):1484-9.
    View in: PubMed
  127. Fay PJ, Smudzin TM. Intersubunit fluorescence energy transfer in human factor VIII. J Biol Chem. 1989 Aug 25; 264(24):14005-10.
    View in: PubMed
  128. Fay PJ, Walker FJ. Inactivation of human factor VIII by activated protein C: evidence that the factor VIII light chain contains the activated protein C binding site. Biochim Biophys Acta. 1989 Feb 2; 994(2):142-8.
    View in: PubMed
  129. Fay PJ. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys. 1988 May 1; 262(2):525-31.
    View in: PubMed
  130. Fay PJ. Subunit structure of thrombin-activated human factor VIIIa. Biochim Biophys Acta. 1988 Jan 29; 952(2):181-90.
    View in: PubMed
  131. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A. 1987 Apr; 84(7):1955-9.
    View in: PubMed
  132. Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein C and protein S. Arch Biochem Biophys. 1987 Jan; 252(1):322-8.
    View in: PubMed
  133. Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood. 1987 Jan; 69(1):27-32.
    View in: PubMed
  134. Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta. 1986 Jun 23; 871(3):268-78.
    View in: PubMed
  135. Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson-Wilhelm BM, Chavin SI, Abraham GN, Handin RI, Orkin SH, et al. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science. 1986 May 23; 232(4753):995-8.
    View in: PubMed
  136. Fay PJ, Cavallaro C, Marder VJ, Pancham N, Fournel MA, Schroeder DD. Comparison of the in vivo survival of human factor VIII with and without von Willebrand factor in the hemophilic dog. Thromb Res. 1986 Feb 1; 41(3):425-9.
    View in: PubMed
  137. Fay PJ, Chavin SI, Malone JE, Schroeder D, Young FE, Marder VJ. The effect of carbohydrate depletion on procoagulant activity and in vivo survival of highly purified human factor VIII. Biochim Biophys Acta. 1984 Jul 30; 800(2):152-8.
    View in: PubMed
  138. LaDuca RJ, Fay PJ, Chuang C, McHenry CS, Bambara RA. Site-specific pausing of deoxyribonucleic acid synthesis catalyzed by four forms of Escherichia coli DNA polymerase III. Biochemistry. 1983 Oct 25; 22(22):5177-88.
    View in: PubMed
  139. Fay PJ, Chavin SI, Schroeder D, Young FE, Marder VJ. Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7200-204.
    View in: PubMed
  140. Fay PJ, Johanson KO, McHenry CS, Bambara RA. Size classes of products synthesized processively by two subassemblies of Escherichia coli DNA polymerase III holoenzyme. J Biol Chem. 1982 May 25; 257(10):5692-9.
    View in: PubMed
  141. Villani G, Fay PJ, Bambara RA, Lehman IR. Elongation of RNA-primed DNA templates by DNA polymerase alpha from Drosophila melanogaster embryos. J Biol Chem. 1981 Aug 10; 256(15):8202-7.
    View in: PubMed
  142. Fay PJ, Johanson KO, McHenry CS, Bambara RA. Size classes of products synthesized processively by DNA polymerase III and DNA polymerase III holoenzyme of Escherichia coli. J Biol Chem. 1981 Jan 25; 256(2):976-83.
    View in: PubMed
  143. Matson SW, Fay PJ, Bambara RA. Mechanism of inhibition of the avian myeloblastosis virus deoxyribonucleic acid polymerase by adriamycin. Biochemistry. 1980 May 13; 19(10):2089-96.
    View in: PubMed
  144. Klubes P, Fay PJ, Cerna I. Effect of chlorpromazine on cell wall biosynthesis and incorporation of orotic acid into nucleic acids in Bacillus megaterium. Biochem Pharmacol. 1971 Feb; 20(2):265-77.
    View in: PubMed
  145. Fay P. Photostimulation of nitrogen fixation in Anabaena cylindrica. Biochim Biophys Acta. 1970 Sep 1; 216(2):353-6.
    View in: PubMed
  146. Fay P, Cox RM. Oxygen inhibition of nitrogen fixation in cell-free preparations of blue-green algae. Biochim Biophys Acta. 1967; 143(3):562-9.
    View in: PubMed
  147. Fay P, Cox RM. Decarboxylation performed by particulate fractions of two nitrogen-fixing blue-green algae. Biochim Biophys Acta. 1966 Oct 10; 126(2):402-4.
    View in: PubMed
  148. COX RM, FAY P, FOGG GE. NITROGEN FIXATION AND PHOTOSYNTHESIS IN A SUBCELLULAR FRACTION OF THE BLUE-GREEN ALGA ANABAENA CYLINDRICA. Biochim Biophys Acta. 1964 Jul 29; 88:208-10.
    View in: PubMed

Visualizations


Fay's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department